Kyverna Therapeutics, Stanford University to evaluate KYV-101 in MS

The company stated: “Kyverna Therapeutics announced the signature of a collaboration agreement with Stanford University to allow the use of KYV-101, an investigational, anti-CD19 CAR T-cell therapy in an open label, phase 1 investigator-initiated trial in nine to twelve adult subjects with non-relapsing and progressive forms of multiple sclerosis. Each participant will receive a single dose of KYV-101. A parallel agreement will support the development of correlative studies thoroughly investigating disease biology upon KYV-101 infusion in MS patients, including the definition of predictors of response and the potential for immune reset. The investigator-initiated trial adds to the Kyverna-sponsored KYSA-7 Phase 2 study in MS and other sponsored KYSA trials in other rheumatological and neurological autoimmune disorders.”